赛诺医疗：近期公司股价累计涨幅较大，可能存在短期上涨过快出现的下跌风险

Core Viewpoint - Sino Medical announced that its stock price has deviated significantly, with a cumulative increase of 200% over 30 consecutive trading days, indicating severe abnormal fluctuations in stock trading [1] Company Summary - The company's daily production and operational status is normal, with no significant changes in market environment or industry policies [1] - The company's subsidiary, Sino Shenchang, has received breakthrough medical device designation from the FDA for its self-expanding intracranial drug-coated stent system (COMETIU) and COMEX balloon microcatheter [1] - The FDA designation does not guarantee that the products will receive approval for market application in the U.S. [1] Stock Performance Summary - As of August 15, the company's stock closed at 34.57 yuan per share, with a significant cumulative increase in stock price that exceeds most of its industry peers and the Shanghai Composite Index [1] - There is a potential risk of a price decline due to the rapid increase in stock price in the short term [1]